

Exonhit announces successful completion of the second phase of EHT Dx14 clinical validation

- EHT Dx14 determinates the exact nature of breast tumors in more than 90% of cases
- Introduction for investigational use in major cancer centers planned in autumn

Paris, France – July 19, 2011 – Following the first data in benign and malignant fine-needle aspiration (FNA) samples communicated on March 29, Exonhit (Alternext: ALEHT) today announced successful completion of the second phase of the validation study of EHT Dx14, a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant ones.

“These excellent results confirm EHT Dx14 ability to identify in almost 80% of indeterminate FNA samples the exact nature of breast tumor. These results combined together with those obtained in benign and malignant FNA samples give a global performance greater than 90% for the test,” said Loïc Maurel, M.D., President of the Management Board of Exonhit. *“EHT Dx14 development demonstrates the power of our technology in the development of high performing molecular signatures.”*

“These results show that EHT Dx14, in association with cytological analysis, could become an alternative to the use of breast biopsies in a large number of cases. They also open very interesting perspectives for strengthening cytology positioning in its contribution to establishing breast cancer diagnosis,” added Philippe Vielh, M.D., Head of the Cytopathological Unit in the Department of Biopathology at the Institut Gustave Roussy in Villejuif (France).

EHT Dx14 clinical validation was a two-step process. It first demonstrated in an independent set of malignant (47) and benign (47) FNA samples coming from the Institut Gustave Roussy biobank, a specificity of 91.5% and a sensitivity of 97.9%.

The purpose of the second validation step was to demonstrate the added value of the test in the discrimination of 55 “difficult” samples for which the cytological analysis did not allow to conclude as it relates to the malignant or benign nature of the sample. The results showed a specificity of 81.8% and a sensitivity of 77.3%. Hence, when cytological analysis gives indeterminate results, EHT Dx14 is able to define the exact nature of breast tumor in close to 4 cases out of 5.

By projection, taking into account the expected frequency of uncertain diagnosis in the general population, the adjusted global performance of EHT Dx14 is 93.4% (post hoc analysis); its specificity is 90.7% and its sensitivity, 96.1%. The test performance adjusted to the Institut Gustave Roussy prevalence is greater than 90% hence demonstrating the excellent performance of EHT Dx14 on the global FNA population processed at Institut Gustave Roussy.

On the basis of these excellent results, Exonhit plans to offer EHT Dx14, as an Investigational Use Only Product, to major cancer centers in France, in autumn 2011.

About EHT Dx14

EHT Dx14 was developed using ExonHit's Genome-Wide SpliceArray™ platform and was licensed from the Institut Gustave Roussy in May 2009. This molecular biology test is intended when assessing a suspicious tumor discovered during mammography to allow the accurate reading of samples obtained by FNA especially in cases where the standard analysis returns an indeterminate result. EHT Dx14 was able during the initial study to differentiate benign breast tumors from malignant ones in 96% of the cases (1).

About Exonhit

Exonhit (Alternext: ALEHT) is a biotech company, focused on personalized medicine, which develops targeted innovative therapeutic and diagnostic products, in oncology and Alzheimer's disease. Exonhit has a balanced development strategy with internal development programs and strategic collaborations, in particular with Allergan.

Exonhit is headquartered in Paris, France and has a U.S. subsidiary in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris and is part of the NYSE Alternext OSEO innovation index. For more information, please visit <http://www.exonhit.com>.

About the Institut Gustave Roussy

The Institut Gustave Roussy (IGR, Villejuif, France), leading European Comprehensive Cancer Center, is a non profit academic entity belonging to the French public hospital service and that is authorized to receive donations and legacies. IGR is a wholly patient-oriented centre with global expertise and the mission to fight cancer. Located South of Paris on a single site, IGR employs 2,500 professionals working in care, research and teaching. Some IGR figures: 337 beds and 83 places for day-cases, 210 certified physicians, 880 professional caregivers, 162,000 consultations and 43,000 patients cared for per year, 27 basic research teams, 300 researchers, and 2800 students, researchers and physicians trained per year. www.igr.fr.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, Exonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

References

(1) André F, Michiels S, Dessen P, Scott V, Suci V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delalogue S. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. *Lancet Oncology* 2009; 10:381-90

Contact for Media & Investors

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com